MarginsXMarginsX
Home › Markets › Health Care › AMLX

Amylyx Pharmaceuticals Inc. (AMLX)

AMLX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$27.80
-8.22% on the day
Market cap
$3.6B
Mid cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$144.7M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1658551/000119312526086645/0001193125-26-086645-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerAMLX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2022
SEC CIK0001658551
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$144.7M
Operating income-$153.3M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$226.7M
Total assets$332.6M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
22.2 months
$240.1M cash at September 30, 2026
Share count, 1 year
+17.1%
2025-10-27 to 2026-10-26 · +90.4% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$9.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$240.1M cash; operating cash flow -$32.5M a quarter.Report 2026-09-30
Shares outstanding128,562,904 (2026-10-26); 109,819,569 a year earlier; 67,517,753 three years earlier.Cover page 2026-10-26
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-08-20
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $152K, sold $9.2M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$45.5M-$33.7M$240.1MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$43.4M-$31.4M$49.3MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2026
2026-03-31
Not filed-$41.3M-$36.9M$229.1MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-12-31
$0-$33.0M-$27.9M$226.7MNo debt tags$010-K 2026-03-03
Q3 2025
2025-09-30
$0-$34.4M-$30.4M$225.2MNo debt tags-$665K10-Q 2025-11-06
Q2 2025
2025-06-30
$0-$41.4M-$25.2M$58.1MNo debt tags-$249K10-Q 2025-08-07
Q1 2025
2025-03-31
$0-$35.9M-$39.8M$59.8MNo debt tags-$1.3M10-Q 2025-05-08
Q4 2024
2024-12-31
-$665K-$37.5M-$59.0M$77.4MNo debt tags$87.4M10-K 2026-03-03

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-08-20
Latest annual report10-K2026-03-03
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-23

Source: SEC EDGAR submissions feed, 448 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.7%
1 month+12.8%
3 months+34.7%
Year to date+150.7%
1 year+143.9%
From 52-week high-23.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PBLSParabilis Medicines Inc.$28.45+0.07%$3.5B
ABCLAbCellera Biologics Inc. Common Shares$11.12-3.22%$3.6B
ELVNEnliven Therapeutics Inc.$47.62-2.42%$3.5B
OGNOrganon & Co. Common Stock$13.900.00%$3.7B
IRONDisc Medicine Inc.$76.59-4.26%$3.5B
ARQTArcutis Biotherapeutics Inc.$27.15-3.93%$3.4B
VKTXViking Therapeutics Inc.$26.80-8.28%$3.4B
VRDNViridian Therapeutics Inc.$29.80-3.47%$3.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier